CRBN Gene Mutations Show Variable Impact on Myeloma Drug Response, Enabling Precision Treatment Selection
Key Insights
Researchers at The Institute of Cancer Research mapped 12 CRBN (search) gene mutations in myeloma (search) cells, revealing that not all mutations equally block immunomodulatory drug effectiveness.
The study found three distinct patterns: some mutations completely disable drug activity, others have no impact, and a third group blocks older IMiDs (search) while allowing newer CELMoDs (search) to remain effective.
Findings suggest clinicians can use mutation-specific data to select appropriate therapies rather than ruling out entire drug classes based on CRBN (search) mutations.
Researchers at The Institute of Cancer Research, London, have demonstrated that specific genetic mutations in the CRBN (search) gene create distinct patterns of drug resistance in myeloma (search), potentially enabling more precise treatment selection for patients with this blood cancer (search). The study, published in the journal Blood, challenges the assumption that all CRBN mutations equally block immunomodulatory drug effectiveness.
Mapping Mutation-Specific Drug Responses
The research team recreated 12 CRBN (search) genetic mutations previously detected in patients by introducing each change into laboratory myeloma (search) cell models. They tested how the altered cells responded to both established immunomodulatory drugs (search) (IMiDs (search)) and newer cereblon E3 ligase modulators (search) (CELMoDs (search)).
Lead author Dr Yakinthi Chrisochoidou, who was a Postdoctoral Research Fellow in the Myeloma (search) Biology and Therapeutics Group at the ICR during the study, conducted the experimental work using models to test how mutations influenced drug response and mapping structural changes at their atomic level.
Three clear patterns emerged from the analysis. Some mutations completely disabled the CRBN (search) gene, stopping all drug activity. Others had no measurable impact, leaving the drugs fully effective. A third group demonstrated drug-specific effects, blocking older IMiDs (search) but allowing newer CELMoDs (search) to continue working.
Structural Insights Drive Treatment Optimization
Structural modeling, supported by a newly generated high-resolution 3D structure of cereblon (search) produced by the research team, helped explain the differential drug responses. CELMoDs (search) are designed to bind more tightly and make additional molecular contacts with the CRBN (search) protein, which may allow them to overcome certain mutations that defeat older drugs.
The CRBN (search) protein serves as the target for IMiDs (search), which act as "molecular glues" to bind to the protein and trigger the destruction of cancer-promoting proteins inside cells. Up to one-third of patients who stop responding to these drugs acquire mutations in the CRBN gene, which encodes the protein that IMiD-type drugs bind to in order to trigger cancer-killing effects.
Clinical Implications for Precision Medicine
The findings could help refine how clinicians interpret genetic test results for myeloma (search) patients. Until now, a mutation in the CRBN (search) gene might have been assumed to signal resistance to all IMiD-type drugs.
Senior Author Dr Charlotte Pawlyn, Group Leader of the Myeloma (search) Biology and Therapeutics Group at the ICR, explained the clinical significance: "As access to myeloma cell sequencing for patients increases, we need to think carefully about what those results mean. It's not as simple as saying, 'You have a mutation, so this drug won't work.' Understanding the biology behind each change helps us tailor treatment choices more accurately."
Broader Impact on Drug Development
The insights could also inform the design of future molecular glue drugs (search), a fast-growing class of precision medicines now being explored beyond myeloma (search). By showing which parts of the CRBN (search) protein are most critical for drug binding, the research highlights how small chemical modifications could make future compounds more resilient to resistance.
Dr Chrisochoidou emphasized the patient-centered goal of the research: "This kind of study helps ensure that we interpret genetic results correctly. Rather than ruling out an entire drug class, we can identify which treatments still have a chance of working – and that's a big step forward."
The work was primarily funded by a Cancer Research UK Clinician Scientist Fellowship grant and supported by additional funding from the Cancer Research Innovation in Science Cancer Foundation and The Institute of Cancer Research.